Repligen Corporation
RGENHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. At a $6.83B market cap, Repligen Corporation ranks as a mid-cap company within healthcare. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Market Cap
$6.83B
Beta
1.09
P/E (TTM)
133.11
P/E (Fwd)
47.56
EPS (TTM)
$0.91
EPS (Fwd)
$2.55
ROE
2.5%
ROA
1.2%
Cash
$784.5M
Total Debt
$687.6M
Free CF
$68.7M
52W Change
-4.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $784.5M in cash comfortably exceeding the $687.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $68.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $670.5M to $738.3M.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Repligen Corporation's trajectory.